@article {Micocci2020.11.02.20224550, author = {Massimo Micocci and Adam L Gordon and A. Joy Allen and Timothy Hicks and Patrick Kierkegaard and Anna McLister and Simon Walne and Peter Buckle and on behalf of the CONDOR study team}, title = {Understanding COVID-19 testing pathways in English care homes to identify the role of point-of-care testing: an interview-based process mapping study}, elocation-id = {2020.11.02.20224550}, year = {2020}, doi = {10.1101/2020.11.02.20224550}, publisher = {Cold Spring Harbor Laboratory Press}, abstract = {Introduction Care home residents are at high risk of dying from COVID-19. Regular testing producing rapid and reliable results is important in this population because infections spread quickly and presentations are often atypical or asymptomatic. This study evaluated current testing pathways in care homes to explore the role of point-of-care tests (POCTs).Methods Ten staff from eight care homes, purposively sampled to reflect care organisational attributes that influence outbreak severity, underwent a semi-structured remote videoconference interview. Transcripts were analysed using process mapping tools and framework analysis focussing on perceptions about, gaps within, and needs arising from, current pathways.Results Four main steps were identified in testing: infection prevention, preparatory steps, swabbing procedure, and management of residents. Infection prevention was particularly challenging for mobile residents with cognitive impairment. Swabbing and preparatory steps were resource-intensive, requiring additional staff resource. Swabbing required flexibility and staff who were familiar to the resident. Frequent approaches to residents were needed to ensure they would participate at a suitable time. After-test management varied between sites. Several homes reported deviating from government guidance to take more cautious approaches, which they perceived to be more robust.Conclusion Swab-based testing is organisationally complex and resource-intensive in care homes. It needs to be flexible to meet the needs of residents and provide care homes with rapid information to support care decisions. POCT could help address gaps but the complexity of the setting means that each technology must be evaluated in context before widespread adoption in care homes.Key-pointsTesting for COVID-19 in care homes is complex and requires reconfiguration of staffing and environment.Isolation and testing procedures are challenged when providing person-centred care to people with dementia.Point-of-care testing results could give care homes greater flexibility to test in person-centred ways.There was evidence that care home staff interpret testing guidance, rather than follow it verbatim.Each POCT must be evaluated in the context of care homes to understand its effect on care home processes.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by UK Research and Innovation (UKRI), Asthma UK and the British Lung Foundation, as a part of the CONDOR study. MM, PK, AML, SW, and PB are supported by the NIHR London In Vitro Diagnostics Co-operative; ALG is funded in part by the NIHR Applied Research Collaboration-East Midlands (ARC-EM); AJA and TH are supported by the NIHR Newcastle In Vitro Diagnostics Co-operative. The views expressed are those of the authors and not necessarily those of the funders, the NHS, the NIHR or the Department of Health and Social Care.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This project was approved as a Service Evaluation by Imperial College Healthcare NHS Trust (ICHNT), registration no. 471All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study are available on request from the corresponding author, [MM]. The data are not publicly available due to their containing information that could compromise the privacy of research participants.}, URL = {https://www.medrxiv.org/content/early/2020/11/04/2020.11.02.20224550}, eprint = {https://www.medrxiv.org/content/early/2020/11/04/2020.11.02.20224550.full.pdf}, journal = {medRxiv} }